Low T3 syndrome is associated with poor prognosis in patients with hepatitis B virus-related acute-on-chronic liver failure. (3rd July 2022)

• Record Type: Journal Article
• Authors: Xiong, Ye; Xia, Zuoxun; Yang, Lu; Huang, Jianrong
• Is Part Of: Expert review of gastroenterology & hepatology. Volume 16:Number 7(2022)
• Page Start: 681
• Page End: 687
• Publication Date: 2022-07-03
• Subjects: Hepatitis B virus-related acute-on-chronic liver failure -- low triiodothyronine syndrome -- mortality -- prognosis -- retrospective; Gastroenterology -- Periodicals; Liver -- Diseases -- Periodicals; 616.3
• DOI: 10.1080/17474124.2022.2090336
• Languages: English
• ISSNs: 1747-4124

Abstract

ABSTRACT: Background: Hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) is a critical disease with high mortality risk. Low triiodothyronine syndrome (LT3S) is associated with various severe acute and chronic diseases. We investigated the relationship between LT3S and poor prognosis in patients with HBV-ACLF. Research design and methods: A total of 198 patients with HBV-ACLF were enrolled between January 2018 and March 2019. We screened for independent risk factors for 28-day mortality using univariate and multivariate logistic regression analyses. Spearman's correlation analysis was used to evaluate the correlation between LT3S and the poor prognostic parameters of HBV-ACLF. Results: LT3S was an independent risk factor for 28-day mortality in HBV-ACLF patients (odds ratio: 4.035, 95% confidence interval 1.117–14.579; p = 0.033). The death group had a lower serum FT3 level (Z-value = 2639.000, p < 0.001). Serum FT3 levels were negatively correlated with age, C-reactive protein, international normalized ratio, and neutrophil count but positively correlated with lymphocyte count. A negative correlation between FT3 and various prognostic scores was observed, indicating that a low FT3 level was closely related to a poor prognosis. Conclusions: LT3S was an independent risk factor for 28-day mortality and was correlated with poor prognosis in patients with HBV-ACLF.